Press release
Polycystic Ovarian Syndrome Industry Insights 2019 by Key Regions & Top Companies are Bayer AG, AstraZeneca plc, Abbott, Biocinese, Catalysis, S.L., Crinetics Pharmaceuticals, Inc., Sanofi, Eugonia, etc
Worldwide Polycystic Ovarian Syndrome Market Report Split Into Several Key Regions, With Sales, Revenue, And Market Share And Growth Rate. Covering North America, Europe, Asia Pacific, Middle East and Africa. And It Is Incorporated On Marketresearchfuture.Com With 100 Pages.Industry Overview:
The polycystic ovarian syndrome market is expected to witness tremendous growth owing to the rising prevalence of polycystic ovarian syndrome. Other key factors such as the growing obesity among women, increase in hormonal disorders in women, change in sedentary lifestyle, socioeconomic factors, growing consumption of unhealthy diet, increasing occurrence of diabetes in women, and others are contributing towards the growth of the market. However, factors such as high cost of diagnostic procedures, expensive treatments, and side effects associated with drugs are expected to hinder the market growth during the forecast period.
Request Free Sample Copy at https://www.marketresearchfuture.com/sample_request/6295
Key Players:
Some of the key players in the global polycystic ovarian syndrome market are Bayer AG, AstraZeneca plc, Abbott, Biocinese, Catalysis, S.L., Crinetics Pharmaceuticals, Inc., Sanofi, Eugonia, EffRx, Inc., Ferring Pharmaceuticals, Inc., Merck KGaA, Bristol-Myer Squibb Company, Neurocrine Biosciences, Inc., Reliance Life Sciences Pvt. Ltd. Pfizer, Inc., Novartis AG, and Shire Plc.
Segmentation:
The global polycystic ovarian syndrome market is segmented on the basis of diagnosis, treatment, and end-user. The polycystic ovarian syndrome market, by diagnosis, is categorized into pelvic examination, transvaginal ultrasound, and blood tests. Blood tests are further sub-segmented into hormone levels, glucose tolerance, and cholesterol and triglyceride levels. On the basis of treatment, the market is segmented into oral contraceptives, antiandrogens, insulin-sensitizing agents, antidepressant, anti-obesity, and surgery. The surgery category includes ovarian wedge resection and laparoscopic ovarian drilling. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers, and others.
Regional Overview:
The Americas is expected to dominate the polycystic ovarian syndrome market during the forecast period. The increasing prevalence of polycystic ovarian syndrome drives the market in this region. According to the Centers for Disease Control and Prevention, the Polycystic Ovary Syndrome (PCOS) affects 6 to 12% of the American women of the childbearing age. This is expected to influence the market growth during the forecast period.
Europe (UK, Belgium, France, and Netherlands) is the second largest in the market owing to the increasing prevalence of obesity and growing healthcare expenditure. The increasing research activities for Polycystic Ovary Syndrome (PCOS) are influencing the market growth. EuroSciCon will hold the 5th World Congress on Polycystic Ovarian Disorder in April 2019 in Berlin, Germany to discuss diagnosis and intervention of the polycystic ovarian syndrome.
Asia-Pacific was projected to be the fastest growing region for the global polycystic ovarian syndrome market in 2017. The market is expected to witness growth owing to the rising prevalence of diabetes in women, changing lifestyle, and growing obesity within the female population. The Asian Diabetes Prevention Initiative estimated that by 2030 India and China will have a diabetic patient pool with a total of half billion people. Furthermore, according to the Journal of the American Medical Association in 2013, China had 187.7 million women suffering from prediabetes. This is expected to provide favorable backgrounds for the market to grow.
The Middle East and Africa accounts for the least share due to stringent government policies and low per capita income.
Browse Complete 100 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at https://www.marketresearchfuture.com/reports/polycystic-ovarian-syndrome-market-6295
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Polycystic Ovarian Syndrome Industry Insights 2019 by Key Regions & Top Companies are Bayer AG, AstraZeneca plc, Abbott, Biocinese, Catalysis, S.L., Crinetics Pharmaceuticals, Inc., Sanofi, Eugonia, etc here
News-ID: 1671667 • Views: …
More Releases from Market Research Future

Global Small Boat Industry Sees Growing Demand Amid Rising Recreational Boating …
As per the latest analysis by Market Research Future, the Small Boats Market Size was estimated at 17.12 (USD Billion) in 2024. The Small Boats Market Industry is expected to grow from 17.88 (USD Billion) in 2025 to 26.41 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 4.43% during the forecast period (2025 - 2034).
The global small boat industry is witnessing significant growth, driven…

Automotive Trim Market Attaining USD 193.22 Billion till 2034 | Innovations Rede …
As per the latest analysis by Market Research Future, the Automotive Trim Market Size was estimated at 140.30 (USD Billion) in 2024. The Automotive Trim Market Industry is expected to grow from 144.87 (USD Billion) in 2025 to 193.22 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 3.25% during the forecast period (2025 - 2034).
The automotive industry is witnessing a significant transformation in vehicle…

Leading Automotive Technology Firms Expand Fuel Level Sensor Solutions for Next- …
As per the latest analysis by Market Research Future, Automotive Fuel Level Sensor Market Size was valued at USD 5,788.04 million in 2024. The Automotive Fuel Level Sensor market industry is projected to grow from USD 6,008.32 million in 2025 to USD 9,201.90 million by 2035, exhibiting a compound annual growth rate (CAGR) of 4.35% during the forecast period (2024 - 2035).
With the global automotive industry focused on precision,…

Valet Parking Technology Gains Momentum as Urban Mobility and Smart Infrastructu …
As per the latest analysis by Market Research Future, the Valet Parking Technology Market Size was estimated at 1.41 (USD Billion) in 2024. The Valet Parking Technology Market Industry is expected to grow from 1.63 (USD Billion) in 2025 to 6.01 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 15.62% during the forecast period (2025 - 2034).
Valet parking technology is emerging as a transformative…
More Releases for Polycystic
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Research
The Global Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market reached with a CAGR during the forecast period 2024-2031.
Autosomal Dominant Polycystic Kidney Disease Market, as detailed in the DataM Intelligence report, presents a strategic overview of the industry backed by in-depth data and market trends. The study highlights the performance and positioning of major players, focusing on their offerings, pricing models, financial outcomes, and growth strategies. It serves as a concise…
Global Efforts to Address Polycystic Ovarian Syndrome (PCOS) Gain Momentum
The Polycystic Ovarian Syndrome (PCOS) Treatment Market is expected to grow from an estimated USD 3514.5 million in 2024 to USD 5546.3 million in 2033, at a CAGR of 5.20%. Global initiatives to raise awareness and address Polycystic Ovarian Syndrome (PCOS) are making significant strides in improving women's health. The World Health Organization (WHO) highlights PCOS as a critical health disorder due to its impact on reproductive health, metabolic well-being,…
Polycystic Kidney Disease Treatment Comprehensive Analysis and Future Estimation …
According to Fact.MR, Insights of Polycystic Kidney Disease Treatment is a specialized and in-depth study of the industry with a special focus on the Key Trends of Polycystic Kidney Disease Treatment as a Service. The report aims to provide an overview with detailed segmentation by type, application, end use and geography. The global is expected to witness high growth during the forecast period.
A survey offers detailed analysis on key growth…
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth.
Browse…
Global Polycystic Ovary Syndrome Market Trends, Size, Forecast - 2018-2023
Polycystic ovary syndrome is a hormonal disorder observed in females of reproductive ages. The disorder causes the excessive production of hormones in the female body, which include testosterone or androgens, hormones that are primarily associated with the male reproductive system. PCOS includes a range of symptoms such as irregular menstrual cycle, trouble in getting pregnant, cyst formation in the ovaries, excessive body and facial hair, and pelvic pain, among…
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).…